Animal model for preeclampsia

• US 7,045,674 B2
• Filed: 09/19/2003
• Issued: 05/16/2006
• Est. Priority Date: 09/19/2002
• Status: Expired due to Fees

• Current Assignee: University of Iowa Research Foundation
• Original Assignee: University of Iowa Research Foundation
• Inventors: Davisson, Robin L.
• Primary Examiner(s): WILSON, MICHAEL C
• Application Number:
  US10/666,980
• Publication Number:
  US 20040133929A1
• Time in Patent Office: 970 Days
• Field of Search: 424/9.1, 424/9.2, 800/3
• US Class Current: 800/3
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure

Abstract

The invention provides an animal model for preeclampsia that allows candidate compounds to be screened for their ability to treat preeclampsia.

Claims

1. A method for screening for compounds useful for the treatment or amelioration of preeclampsia and/or the symptoms thereof comprising:

inducing preeclampsia in a BPH/5 mouse;

administering a test compound to the mouse; and

monitoring the mouse for amelioration or elimination of preeclampsia or its symptoms, wherein amelioration or elimination of preeclampsia or its symptoms in the mouse indicates usefulness of the compound for the treatment of preeclampsia.

2. The method of clam 1, wherein preeclampsia is induced by mating the BPH/5 mouse with another mouse such that the BPH/5 mouse becomes pregnant.

3. A method for screening for compounds useful for the treatment of preeclampsia comprising:

mating a female BPH/5 mouse with another mouse wherein the BPH/5 mouse becomes pregnant and exhibits preeclampsia;

administering a test compound to the pregnant BPH/5 mouse; and

monitoring the pregnant BPH/5 mouse for amelioration or elimination of preeclampsia, wherein amelioration or elimination of preeclampsia in the pregnant BPH/5 mouse indicates usefulness of the compound for the treatment of preeclampsia.

4. A method of screening a candidate compound for alleviating preeclampsia, said method comprising:

inducing preeclampsia in a BPH5 mouse by impregnating said mouse;

administering a compound to said BPH/5 mouse; and

comparing the induced preeclampsia condition in said BPH/5 mouse with the induced preeclampsia condition in a control BPH/5 mouse that did not receive said candidate compound, wherein an amelioration or elimination in the preeclampsia condition of the treated BPH/5 mouse is indicative of the alleviating activity of said candidate compound.

5. A method of screening a candidate compound for the prevention of preeclampsia, said method comprising:

administering a compound to a BPH/5 mouse;

inducing pregnancy in said mouse; and

comparing the pregnant condition in said mouse with said candidate agent with a pregnant control BPH/5 mouse exhibiting preeclampsia, wherein the prevention or reduction of the affects of the preeclampsia condition of the treated mouse is indicative of the alleviating activity of said candidate compound.